Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-24

MapLight Therapeutics (MPLT)

CEO Christopher Kroeger was paid $25,624,254 in fiscal year 2025 (SEC filing 0001193125-26-191449 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$25,624,254
Christopher Kroeger total, FY2025
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
—
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Christopher Kroeger (President and Chief Executive Officer), FY2025 total compensation $25,624,254 (base salary $655,250) [exec_comp, SEC accession 0001193125-26-191449, filed 2026-04-29]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

MPLT's next annual pay disclosure, estimated April 29, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Christopher Kroeger$655,250$0$12,296,267$12,322,406$331,000$0$19,331$25,624,254
President and Chief Executive Officer
Erin Foff531,00002,871,4782,636,670194,000020,8516,254,000
Chief Medical Officer
Vishwas Setia432,29403,200,5002,367,617183,000019,1536,202,564
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Christopher Kroeger$25,624,254———
Erin Foff6,254,000———
Vishwas Setia6,202,564———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read MapLight Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper MPLT reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against MPLT
No companies currently name MPLT as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Christopher KroegerCEO$25,624,254
Vishwas SetiaCFO$6,202,564
Erin FoffChief Medical Officer$6,254,000
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
George PavlovChair of the Board$9,663
Jim Trenkle, Ph.DIndependent Director—
Maria WalkerIndependent Director$895,183
Nanna Lüneborg, Ph.DIndependent Director$10,584
Robert Malenka, M.D., Ph.DIndependent Director$3,217,650
Timothy Garnett, M.B.B.SIndependent Director$728,403
02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Christopher KroegerRSU56,204—$987,223
Christopher KroegerRSU225,693—3,964,298
Vishwas SetiaRSU72,743—1,277,731
Christopher KroegerRSU853,459—14,991,007
Erin FoffOption1,2905.55—
Vishwas SetiaRSU248,513—4,365,131
Christopher KroegerOption916,16417—
Christopher KroegerRSU218,094—3,830,821
Erin FoffRSU206,901—3,634,216
Erin FoffRSU21,208—372,519
Christopher KroegerRSU94,017—1,651,409
Erin FoffRSU57,155—1,003,928
Erin FoffRSU48,275—847,950
Vishwas SetiaRSU43,367—761,741
Erin FoffRSU11,335—199,099
Christopher KroegerOption3,0705.55—
Vishwas SetiaOption176,03117—
Erin FoffOption82,6195.55—
Erin FoffOption196,03517—
05

Incentive-plan design — the Compensation Discussion & Analysis

We consider compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as compared to our expectations and objectives, and our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders and to incentivize a long-term commitment to our company.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantPay Governance LLC
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-23—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-23—a

a. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)—
CEO total compensation—
Median employee compensation—
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Robert Malenka, M.D., Ph.DIndependent · Not standing for re-election$7,363$1,192,533$1,877,755—$140,000$3,217,650
Maria WalkerIndependent · Audit (Chair)51,841498,968344,374—0895,183
Timothy Garnett, M.B.B.SIndependent · Compensation (Chair) · Nominating and Corporate Governance51,841332,189344,374—0728,403
Nanna Lüneborg, Ph.DIndependent · Audit · Compensation10,58400—010,584
George PavlovIndependent · Board Chair · Compensation · Nominating and Corporate Governance9,66300—09,663
Christopher A. Kroeger, M.DEmployee director—————0
Jim Trenkle, Ph.DIndependent · Audit · Nominating and Corporate Governance (Chair) · Not standing for re-election000—00
Martin BablerIndependent · Newly elected——————
Troy CoxIndependent · Nominating and Corporate Governance · Newly elected——————
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$131,292
Equity awards (grant-date value)$2,023,690
All other compensation$140,000
Total cost of the board$2,294,982

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1MapLight Therapeutics2025Christopher Kroeger$655,250$12,296,267$12,322,406$331,000$25,624,254

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at MapLight Therapeutics in fiscal 2025?
As disclosed, Christopher Kroeger (President and Chief Executive Officer) was the highest-paid executive at MapLight Therapeutics in fiscal 2025, with total compensation of $25,624,254.
How much does MapLight Therapeutics spend in total on board compensation for fiscal 2025?
As disclosed, MapLight Therapeutics reported total board compensation of $2,294,982 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Christopher KroegerDEF 14A2026-04-290001193125-26-191449Section “SUMMARY COMPENSATION TABLE”. As printed: 25,624,254. Filing ↗machine: r2 · c26 · span 218198–218208
2Section 01, Erin FoffDEF 14A2026-04-290001193125-26-191449Section “SUMMARY COMPENSATION TABLE”. As printed: 6,254,000. Filing ↗machine: r6 · c26 · span 226904–226913
3Section 01, Vishwas SetiaDEF 14A2026-04-290001193125-26-191449Section “SUMMARY COMPENSATION TABLE”. As printed: 6,202,564. Filing ↗machine: r4 · c26 · span 222579–222588
4Section 07, pay ratio10-K2026-03-260001193125-26-125072Section “CEO Pay Ratio”. As printed: —. Filing ↗
5Section 08, Robert Malenka, M.D., Ph.DDEF 14A2026-04-290001193125-26-191449Section “Director Compensation”. As printed: 3,217,650. Filing ↗machine: span 324377–324386
6Section 08, Maria WalkerDEF 14A2026-04-290001193125-26-191449Section “Director Compensation”. As printed: 895,183. Filing ↗machine: span 329307–329314
7Section 08, Timothy Garnett, M.B.B.SDEF 14A2026-04-290001193125-26-191449Section “Director Compensation”. As printed: 728,403. Filing ↗machine: span 321002–321009
8Section 08, Nanna Lüneborg, Ph.DDEF 14A2026-04-290001193125-26-191449Section “Director Compensation”. As printed: 10,584. Filing ↗machine: span 321556–321562
9Section 08, George PavlovDEF 14A2026-04-290001193125-26-191449Section “Director Compensation”. As printed: 9,663. Filing ↗machine: span 324920–324925
10Section 08, Christopher A. Kroeger, M.DDEF 14A2026-04-290001193125-26-191449Section “Director Compensation”. As printed: 0. Filing ↗
11Section 08, Jim Trenkle, Ph.DDEF 14A2026-04-290001193125-26-191449Section “Director Compensation”. As printed: 0. Filing ↗
12Section 08, Martin BablerDEF 14A2026-04-290001193125-26-191449Section “Director Compensation”. As printed: —. Filing ↗
13Section 08, Troy CoxDEF 14A2026-04-290001193125-26-191449Section “Director Compensation”. As printed: —. Filing ↗
14Section 06, 2026 voteForm 8-K2026-06-240001193125-26-280243Item 5.07 · say-on-pay result. As reported: —. Filing ↗
15Section 09b board cost (computed)Computed——Cash 131,292 + equity 2,023,690 + all other 140,000 = 2,294,982, summed across the director compensation table rows.machine: formula: Σ = 2,294,982
16MapLight Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-290001193125-26-191449CEO total compensation as printed in MapLight Therapeutics's own proxy. As printed: 25,624,254. Filing ↗machine: r2 · c26 · span 218198–218208

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.